Drug Trial Radar · NCT00007631
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
Last checked: Nov 19, 2026Latest source record: Jan 30, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,131
Actual
Start
Mar 1998
Primary completion
Nov 2004
Study completion Jul 2006
Sponsor
- Lead sponsor
- US Department of Veterans AffairsFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Ortho Dermatologics
- First posted
- Jan 1, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
One-third of all malignancies in the United States (approximately one million cases diagnosed annually) are nonmelanoma skin cancer (NMSC). NMSC causes considerable morbidity, economic burden, facial deformity and at least 1,000 deaths annually. Prevention of these malignancies with a topical agent free of serious side effects would confer substantial public health benefit. Three hundred fifty thousand veterans were expected to develop NMSC in 1994. NMSC is one of the most common conditions requiring dermatologic care in the VA system. Topical tretinoin has been used extensively to treat photoaged skin. Retinoids administered orally in high doses appear to be effective in chemoprevention of nonmelanoma skin cancer but have unacceptable toxicity. In this study, 1131 patients with a recent history of squamous cell and/or basal cell carcinoma were enrolled at six participating centers over a four-year period and were randomly assigned to either 0.1% tretinoin cream or placebo. They were followed for a minimum of two years to determine if topical tretinoin is effective in reducing the risk of new occurrences.
Conditions
- Carcinoma, Basal Cell
- Carcinoma, Squamous Cell
- Skin Neoplasms
Interventions
Tretinoin 0.1% cream or placeboDrug
PlaceboOther
Patients receive placebo for same amount of time
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long term effect of topical tretinoin on the prevalence of premalignant actinic keratosesTime frame: until the end of the study for a minimum of 2 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Carl T. Hayden VA Medical Center
Phoenix, Arizona
VA Medical Center, Long Beach
Long Beach, California
VA Medical Center, Miami
Miami, Florida
Edward Hines, Jr. VA Hospital
Hines, Illinois
VA Medical Center, Durham
Durham, North Carolina
VA Medical Center, Oklahoma City
Oklahoma City, Oklahoma
VA Medical Center, Providence
Providence, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.